NCT00493896View on ClinicalTrials.gov

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

PHASE3TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Venous Thromboembolism

Interventions

DRUG

Fondaparinux

The dose for Arixtra is 2.5 mg once daily, subcutaneously.

DRUG

Enoxaparin

The dose for Lovenox is 40 mg once daily, subcutaneously.

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Eastern Virginia Medical School

OTHER

NCT00493896 - Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients | Biotech Hunter | Biotech Hunter